Japan approves GSK’s Sotrovimab COVID-19 antibody treatment By Reuters
[ad_1]
2/2
© Reuters. FILE PHOTO A GlaxoSmithKline logo can be seen in Stevenage (Britain) November 26, 2019. REUTERS/Peter Nicholls
2/2
© Reuters. FILE PHOTO A GlaxoSmithKline logo can be seen in Stevenage (Britain) November 26, 2019. REUTERS/Peter Nicholls2/2
TOKYO (Reuters) – Japan has approved GlaxoSmithKline (NYSE:) and Vir Biotechnology (NASDAQ:)’s Sotrovimab as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.
GSK stated that the antibody treatment was for COVID-19 mild-to-moderate cases and does not require oxygen supplementation when applying for fast track approval.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. Instead, they are determined by marketmakers. As such, the prices might not reflect market conditions and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]